Citations (50)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Huan Zhang, Cheng Yu, Yuanling Cheng, Zhi Chen, Min Chen, Wangan He, Zhigang Jin, Shaoqian Cai & Lijuan Yu. (2023) Clinical Trials in Hypertrophic Cardiomyopathy Therapy: A Comprehensive Analysis of Trials Registered in Global Clinical Databases. Drug Design, Development and Therapy 17, pages 1863-1877.
Read now
Read now
Tiffany Dong, Ben Alencherry, Susan Ospina & Milind Y Desai. (2023) Review of Mavacamten for Obstructive Hypertrophic Cardiomyopathy and Future Directions. Drug Design, Development and Therapy 17, pages 1097-1106.
Read now
Read now
Akiva Rosenzveig, Neil Garg, Shiavax J. Rao, Amreen K. Kanwal, Arjun Kanwal, Wilbert S. Aronow & Matthew W. Martinez. (2023) Current and emerging pharmacotherapy for the management of hypertrophic cardiomyopathy. Expert Opinion on Pharmacotherapy 24:12, pages 1349-1360.
Read now
Read now
Siva Nageswara Rao Gajula, Sasikala Talari, Tanaaz Navin Nathani, Vijay Munjal, Ziaur Rahman, Manoj P Dandekar & Rajesh Sonti. (2023) Effect of Chronopharmacology and Food on in Vivo Pharmacokinetic Profile of Mavacamten. Bioanalysis 15:12, pages 695-706.
Read now
Read now
Tiffany Dong, Steven Nissen, Susan Ospina & Milind Y Desai. (2023) An evaluation of mavacamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy in adults. Expert Review of Cardiovascular Therapy 21:1, pages 5-13.
Read now
Read now
Juan Tamargo, María Tamargo & Ricardo Caballero. (2022) Hypertrophic cardiomyopathy: an up-to-date snapshot of the clinical drug development pipeline. Expert Opinion on Investigational Drugs 31:10, pages 1027-1052.
Read now
Read now
Albree Tower-Rader, Jay Ramchand, Steve E. Nissen & Milind Y. Desai. (2020) Mavacamten: a novel small molecule modulator of β-cardiac myosin for treatment of hypertrophic cardiomyopathy. Expert Opinion on Investigational Drugs 29:11, pages 1171-1178.
Read now
Read now
Articles from other publishers (43)
Jiangtao Li, Jing Fang, Yani Liu & Xiang Wei. (2023) Apical hypertrophic cardiomyopathy: pathophysiology, diagnosis and management. Clinical Research in Cardiology 113:5, pages 680-693.
Crossref
Crossref
Colleen M. Kelly, Jody L. Martin & Michael J. Previs. (2024) Myosin folding boosts solubility in cardiac muscle sarcomeres. JCI Insight 9:8.
Crossref
Crossref
Alyssa Sykuta, Connie H. Yoon, Sarah Baldwin, Natalie I. Rine, Michael Young & Adam Smith. (2023) Cardiac Myosin Inhibitors: Expanding the Horizon for Hypertrophic Cardiomyopathy Management. Annals of Pharmacotherapy 58:3, pages 273-285.
Crossref
Crossref
Andrew Wang, John A. Spertus, Daniel M. Wojdyla, Theodore P. Abraham, Ester Kim Nilles, Anjali Tiku Owens, Sara Saberi, Sharon Cresci, Amy Sehnert & Neal K. Lakdawala. (2024) Mavacamten for Obstructive Hypertrophic Cardiomyopathy With or Without Hypertension. JACC: Heart Failure 12:3, pages 567-579.
Crossref
Crossref
Vijaya Madhyanapu Golla, Mallika Kalyan, Upasana Gholap, Hara Prasad Padhy, Roshitha K. Ramachandran & Gananadhamu Samanthula. (2024)
Discerning the stability behaviour of mavacamten availing liquid chromatography‐mass spectrometry and nuclear magnetic resonance spectroscopy:
In silico
toxicity and mutagenicity prediction of degradation products
. Journal of Mass Spectrometry 59:3.
Crossref
Crossref
Jacob M. Blair, Gary S. Kabinoff & Matthew D. Kay. (2024) Painful Diplopia Associated With Mavacamten Use: A Case Report. Journal of Neuro-Ophthalmology.
Crossref
Crossref
Florian Rader, Artur Oręziak, Lubna Choudhury, Sara Saberi, David Fermin, Matthew T. Wheeler, Theodore P. Abraham, Pablo Garcia-Pavia, Donna R. Zwas, Ahmad Masri, Anjali Owens, Sheila M. Hegde, Tim Seidler, Shawna Fox, Ganesh Balaratnam, Amy J. Sehnert & Iacopo Olivotto. (2024) Mavacamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure 12:1, pages 164-177.
Crossref
Crossref
Jorik H. Amesz, Sanne J.J. Langmuur, Lu Zhang, Olivier C. Manintveld, Arend F.L. Schinkel, Peter L. de Jong, Natasja M.S. de Groot & Yannick J.H.J. Taverne. (2024) Biomechanical response of ultrathin slices of hypertrophic cardiomyopathy tissue to myosin modulator mavacamten. Biomedicine & Pharmacotherapy 170, pages 116036.
Crossref
Crossref
Ram B. Singh, Jaipaul Singh, Keshore Bidasee, Adrian Isaza, Sunil Rupee, Khemraj Rupee, Carlin Hanoman, Ernest Adeghate & Manal M.A. Smail. 2024. Pathophysiology, Risk Factors, and Management of Chronic Heart Failure. Pathophysiology, Risk Factors, and Management of Chronic Heart Failure
103
113
.
Mariem A. Sawan, Sindhu Prabakaran, Melroy D'Souza, Omid Behbahani‐Nejad, Matthew E. Gold, Byron Robinson Williams & Ozlem Bilen. (2024) A systematic review of present and future pharmaco‐structural therapies for hypertrophic cardiomyopathy. Clinical Cardiology 47:1.
Crossref
Crossref
Hussain Sohail Rangwala, Hareer Fatima, Mirha Ali, Syed Taha Ahmed, Burhanuddin Sohail Rangwala & Syed Raza Abbas. (2023) Analyzing safety and effectiveness of Mavacamten in comparison with placebo for managing hypertrophic cardiomyopathy: a systemic review and meta-analysis. The Egyptian Heart Journal 75:1.
Crossref
Crossref
Matthew M. Y. Lee & Ahmad Masri. (2023) Differentiating Cardiac Troponin Levels During Cardiac Myosin Inhibition or Cardiac Myosin Activation Treatments: Drug Effect or the Canary in the Coal Mine?. Current Heart Failure Reports 20:6, pages 504-518.
Crossref
Crossref
Vidya Perera, Daniel D. Gretler, Julie D. Seroogy, Manting Chiang, Maria Palmisano & Victoria Florea. (2023) Effects of Omeprazole and Verapamil on the Pharmacokinetics, Safety, and Tolerability of Mavacamten: Two Drug–Drug Interaction Studies in Healthy Participants. Clinical Pharmacology in Drug Development 12:12, pages 1241-1251.
Crossref
Crossref
Eugene Braunwald, Sara Saberi, Theodore P Abraham, Perry M Elliott & Iacopo Olivotto. (2023) Mavacamten: a first-in-class myosin inhibitor for obstructive hypertrophic cardiomyopathy. European Heart Journal 44:44, pages 4622-4633.
Crossref
Crossref
Manting Chiang, Caroline Sychterz, Lu Gaohua, Vidya Perera, Daniel D. Gretler, Victoria Florea & Samira Merali. (2023) Drug–Drug Interaction Potential of Mavacamten with Oral Contraceptives: Results from a Clinical Pharmacokinetic Study and a Physiologically Based Pharmacokinetic Model. The Journal of Clinical Pharmacology 63:11, pages 1275-1282.
Crossref
Crossref
Smita Scholtz, Volker Rudolph & Jan-Christian Reil. (2023) Alcohol Septal Ablation or Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Journal of Clinical Medicine 12:20, pages 6628.
Crossref
Crossref
Manting Chiang, Caroline Sychterz, Vidya Perera, Samira Merali, Maria Palmisano, Ian E. Templeton & Lu Gaohua. (2023) Physiologically Based Pharmacokinetic Modeling and Simulation of Mavacamten Exposure with Drug–Drug Interactions from CYP Inducers and Inhibitors by CYP2C19 Phenotype. Clinical Pharmacology & Therapeutics 114:4, pages 922-932.
Crossref
Crossref
Simrat Kaur & Milind Desai. (2023) Unmet needs and future directions in hypertrophic cardiomyopathy. Progress in Cardiovascular Diseases 80, pages 1-7.
Crossref
Crossref
Sneha Annie Sebastian, Inderbir Padda, Eric J. Lehr & Gurpreet Johal. (2023) Aficamten: A Breakthrough Therapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy. American Journal of Cardiovascular Drugs 23:5, pages 519-532.
Crossref
Crossref
Anna Burban, Szymon Pucyło, Aleksandra Sikora, Grzegorz Opolski, Marcin Grabowski & Agnieszka Kołodzińska. (2023) Hypertrophic Cardiomyopathy versus Storage Diseases with Myocardial Involvement. International Journal of Molecular Sciences 24:17, pages 13239.
Crossref
Crossref
Fernando Saraiva, Fabio Fernandes, Minna Moreira Dias Romano, Juliano Novaes Cardoso, Marília Taily Soliani, Mariani Mendes Madison, André Schmidt & Marcus Vinicius Simões. (2023) Diagnosis and Treatment of Hypertrophic Cardiomyopathy. ABC Heart Fail Cardiomyop 3:1.
Crossref
Crossref
Qingqing Li, Ya-nan Liu, Chaojie Chen, Ren-ai Xu, Saili Xie & Ruanjuan Zhan. (2023) Effects of CYP2C19 inhibitors on mavacamten pharmacokinetics in rats based on UPLC-MS/MS. Chemico-Biological Interactions 380, pages 110531.
Crossref
Crossref
Ma’Lik Woodland & Rami A. Al-Horani. (2023) New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy. Cardiovascular & Hematological Agents in Medicinal Chemistry 21:2, pages 78-83.
Crossref
Crossref
John W. Ostrominski, Ruby Guo, Perry M. Elliott & Carolyn Y. Ho. (2023) Cardiac Myosin Inhibitors for Managing Obstructive Hypertrophic Cardiomyopathy. JACC: Heart Failure 11:7, pages 735-748.
Crossref
Crossref
Ashley Schenk & Nathan Fields. (2023) Mavacamten—A Targeted Therapy for Hypertrophic Cardiomyopathy. Journal of Cardiovascular Pharmacology 81:5, pages 317-326.
Crossref
Crossref
Asra K. Butt, Deya Alkhatib, Issa Pour-Ghaz, Sakiru Isa, Omar Al-Taweel, Ifeoma Ugonabo, Neeraja Yedlapati & John Lynn Jefferies. (2023) Hypertrophic Cardiomyopathy. Journal of Cardiovascular Development and Disease 10:3, pages 106.
Crossref
Crossref
Safia Chatur & Sheila M. Hegde. (2023) Monitoring treatment with cardiac myosin inhibitors in symptomatic obstructive cardiomyopathy. Current Opinion in Cardiology Publish Ahead of Print.
Crossref
Crossref
Michael J. Capilupi & William H. Frishman. (2022) Mavacamten: A Novel Disease-Specific Treatment for Hypertrophic Cardiomyopathy. Cardiology in Review 31:1, pages 45-51.
Crossref
Crossref
Mahmoud Ismayl, Muhannad Aboud Abbasi, Rosalyn Marar, Jeffrey B. Geske, Bernard J. Gersh & Nandan S. Anavekar. (2023) Mavacamten Treatment for Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Current Problems in Cardiology 48:1, pages 101429.
Crossref
Crossref
Tiago Aguiar & Elisabete Martins. (2022) Mavacamten, a novel revolutionizing therapy in hypertrophic obstructive cardiomyopathy: A literature review. Revista Portuguesa de Cardiologia 41:8, pages 693-703.
Crossref
Crossref
Fady I. Malik, Laura A. Robertson, Danielle R. Armas, Edward P. Robbie, Anna Osmukhina, Donghong Xu, Hanbin Li & Scott D. Solomon. (2022) A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants. JACC: Basic to Translational Science 7:8, pages 763-775.
Crossref
Crossref
Susan J. Keam. (2022) Mavacamten: First Approval. Drugs 82:10, pages 1127-1135.
Crossref
Crossref
Sarah J. Lehman, Claudia Crocini & Leslie A. Leinwand. (2022) Targeting the sarcomere in inherited cardiomyopathies. Nature Reviews Cardiology 19:6, pages 353-363.
Crossref
Crossref
Nihar Desai, Jipan Xie, Yan Wang, Megan B. Sutton, John Whang, Jennifer T. Fine & Louis P. GarrisonJrJr. (2022) Projecting the Long-term Clinical Value of Mavacamten for the Treatment of Obstructive Hypertrophic Cardiomyopathy in the United States: An Assessment of Net Health Benefit. Clinical Therapeutics 44:1, pages 52-66.e2.
Crossref
Crossref
Alejandro de Feria & Anjali T. Owens. (2021) Novel therapies in inherited cardiomyopathies. Progress in Pediatric Cardiology 63, pages 101444.
Crossref
Crossref
Sheila M. Hegde, Steven J. Lester, Scott D. Solomon, Michelle Michels, Perry M. Elliott, Sherif F. Nagueh, Lubna Choudhury, David Zemanek, Donna R. Zwas, Daniel Jacoby, Andrew Wang, Carolyn Y. Ho, Wanying Li, Amy J. Sehnert, Iacopo Olivotto & Theodore P. Abraham. (2021) Effect of Mavacamten on Echocardiographic Features in Symptomatic Patients With Obstructive Hypertrophic Cardiomyopathy. Journal of the American College of Cardiology 78:25, pages 2518-2532.
Crossref
Crossref
Chihyuan Chuang, Scott Collibee, Luke Ashcraft, Wenyue Wang, Mark Vander Wal, Xiaolin Wang, Darren T. Hwee, Yangsong Wu, Jingying Wang, Eva R. Chin, Peadar Cremin, Jeanelle Zamora, James Hartman, Julia Schaletzky, Eddie Wehri, Laura A. Robertson, Fady I. Malik & Bradley P. Morgan. (2021) Discovery of Aficamten (CK-274), a Next-Generation Cardiac Myosin Inhibitor for the Treatment of Hypertrophic Cardiomyopathy. Journal of Medicinal Chemistry 64:19, pages 14142-14152.
Crossref
Crossref
Milind Y. Desai, Kathy Wolski, Anjali Owens, Srihari S. Naidu, Jeffrey B. Geske, Nicholas G. Smedira, Hartzell Schaff, Kathy Lampl, Ellen McErlean, Christina Sewell, David Zhang, Jay M. Edelberg, Amy J. Sehnert & Steven E. Nissen. (2021) Study design and rationale of VALOR-HCM: evaluation of mavacamten in adults with symptomatic obstructive hypertrophic cardiomyopathy who are eligible for septal reduction therapy. American Heart Journal 239, pages 80-89.
Crossref
Crossref
Yu-Jen Chen, Chian-Shiu Chien, Chern-En Chiang, Chen-Huan Chen & Hao-Min Cheng. (2021) From Genetic Mutations to Molecular Basis of Heart Failure Treatment: An Overview of the Mechanism and Implication of the Novel Modulators for Cardiac Myosin. International Journal of Molecular Sciences 22:12, pages 6617.
Crossref
Crossref
Khulud Alsulami & Steven Marston. (2020) Small Molecules Acting on Myofilaments as Treatments for Heart and Skeletal Muscle Diseases. International Journal of Molecular Sciences 21:24, pages 9599.
Crossref
Crossref
Peter O. Awinda, Yemeserach Bishaw, Marissa Watanabe, Maya A. Guglin, Kenneth S. Campbell & Bertrand C. W. Tanner. (2020)
Effects of mavacamten on Ca
2+
sensitivity of contraction as sarcomere length varied in human myocardium
. British Journal of Pharmacology 177:24, pages 5609-5621.
Crossref
Crossref
Iacopo Olivotto, Artur Oreziak, Roberto Barriales-Villa, Theodore P Abraham, Ahmad Masri, Pablo Garcia-Pavia, Sara Saberi, Neal K Lakdawala, Matthew T Wheeler, Anjali Owens, Milos Kubanek, Wojciech Wojakowski, Morten K Jensen, Juan Gimeno-Blanes, Kia Afshar, Jonathan Myers, Sheila M Hegde, Scott D Solomon, Amy J Sehnert, David Zhang, Wanying Li, Mondira Bhattacharya, Jay M Edelberg, Cynthia Burstein Waldman, Steven J Lester, Andrew Wang, Carolyn Y Ho, Daniel Jacoby, Jozef Bartunek, Antoine Bondue, Emeline Van Craenenbroeck, Milos Kubanek, David Zemanek, Morten Jensen, Jens Mogensen, Jens Jakob Thune, Philippe Charron, Albert Hagege, Olivier Lairez, Jean-Noël Trochu, Christoph Axthelm, Hans-Dirk Duengen, Norbert Frey, Veselin Mitrovic, Michael Preusch, Jeanette Schulz-Menger, Tim Seidler, Michael Arad, Majdi Halabi, Amos Katz, Daniel Monakier, Offir Paz, Samuel Viskin, Donna Zwas, Iacopo Olivotto, Hans Peter Brunner-La Rocca, Michelle Michels, Dariusz Dudek, Zofia Oko-Sarnowska, Artur Oreziak, Wojciech Wojakowski, Nuno Cardim, Helder Pereira, Roberto Barriales-Villa, Pablo García Pavia, Juan Gimeno Blanes, Rafael Hidalgo Urbano, Luis Miguel Rincón Diaz, Perry Elliott, Zaheer Yousef, Theodore Abraham, Kia Afshar, Paulino Alvarez, Richard Bach, Richard Becker, Lubna Choudhury, David Fermin, Daniel Jacoby, John Jefferies, Christopher Kramer, Neal Lakdawala, Steven Lester, Ali Marian, Ahmad Masri, Mathew Maurer, Sherif Nagueh, Anjali Owens, David Owens, Florian Rader, Sara Saberi, Mark Sherrid, Jamshid Shirani, John Symanski, Aslan Turer, Andrew Wang, Omar Wever-Pinzon, Matthew Wheeler, Timothy Wong & Mohamad Yamani. (2020) Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet 396:10253, pages 759-769.
Crossref
Crossref
A. V. Lysenko, P. V. Lednev, G. I. Salagaev, G. V. Sinyavin, E. V. Barinov, A. M. Grabuzdov & Yu. V. Belov. (2019) The modern view on the diagnosis and treatment of hypertrophic cardiomyopathy. Kardiologiya i serdechno-sosudistaya khirurgiya 12:1, pages 38.
Crossref
Crossref